U.S. Department of Health and Human Services; National Institutes of Health; NIH News; National Institute of Allergy and Infectious Diseases (NIAID) - Thursday, September 4, 2008
CONTACT: Laura Sivitz, 301-402-1663, e-mail:niaidnews@niaid.nih.gov
Scientists have uncovered new evidence that strengthens the link between a host-cell gene called Apobec3 and the production of neutralizing antibodies to retroviruses. Published in the Sept. 5 issue of Science, the finding adds a new dimension to the set of possible explanations for why most people who are infected wit
After soliciting and considering broad input from the scientific and HIV advocacy communities, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has determined that it will not conduct the HIV vaccine study known as PAVE 100. However, NIAID believes the
CONTACT: NIAID Office of Communications, 301-402-1663, niaidnews@niaid.nih.gov
WHAT: Recent studies have shown that HIV causes a vigorous and prolonged immune response that eventually leads to the exhaustion of key immune system cells--CD4+ and CD8+ T-cells--that target HIV. These tired cells become less and less able to fight the virus, and the cells fatigue contributes to the inability of an HI
NIAID Office of Communications: 301-402-1663, niaidnews@niaid.nih.gov
Interim results from a clinical study indicate that the anti-tuberculosis (TB) drug isoniazid is safe but ineffective in preventing TB or death in infants who at the time of enrollment had no history of TB exposure or disease and were either HIV-infected or HIV-exposed but uninfected. An independent data and safety mon
U.S. Department of Health and Human Services; National Institutes Of Health; NIH News; National Institute of Allergy and Infectious Diseases (NIAID) - Wednesday, June 25, 2008
CONTACT: Laura Sivitz, 301-402-1663, e-mail:sivitzl@niaid.nih.gov
To accelerate the translation of basic discoveries about HIV into advances in vaccine design and evaluation, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has formed a new Vaccine Discovery Branch within the Vaccine Research Program in the Division o
On Friday, May 30, 2008, the AIDS Vaccine Research Subcommittee (AVRS), a component of the National Institute of Allergy and Infectious Diseases (NIAID) AIDS Research Advisory Committee, will meet in Bethesda, Md., to discuss the proposed HIV vaccine study known as PAVE 100. The meeting will begin at 8:30 a.m. and end
An independent Data and Safety Monitoring Board (DSMB) has determined that the experimental, once-daily antiretroviral drug regimen of emtricitabine, atazanavir and didanosine enteric-coated (ddI-EC) is inferior to a standard antiretroviral drug regimen and therefore should be discontinued in an ongoing clinical trial.
U.S. Department of Health and Human Services; National Institutes Of Health; NIH News; National Institute of Allergy and Infectious Diseases (NIAID) - Tuesday, May 20, 2008
CONTACT: Laura Sivitz, 301-402-1663, e-mail:sivitzl@niaid.nih.gov
To advance underdeveloped approaches to designing a preventive HIV vaccine, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is launching a new program to foster the study of B cells, immune cells that can produce antibodies with the capacity to neutralize HI
NIAID is launching a new research program to advance underdeveloped approaches to designing a preventive HIV vaccine. This $15.6 million, five-year program will foster the study of B cells, immune cells that can produce antibodies with the capacity to neutralize HIV. HIV is devilishly good at fooling B cells and shield
U.S. Department of Health and Human Services; National Institutes Of Health; NIH News; National Institute of Allergy and Infectious Diseases (NIAID) - Monday, May 19, 2008
Statement of Anthony S. Fauci, M.D., Director, National Institute Of Allergy And Infectious Diseases, on National Asian and Pacific Islander HIV/AIDS Awareness Day, May 19, 2008 The HIV/AIDS epidemic has emerged to clearly threaten the public health of Asians and Pacific Islanders living in the United States
National Institute of Allergy and Infectious Diseases; National Institutes of Health
NIAID Online Update - May 16, 2008
Twenty-five years ago this month, researchers uncovered the virus that causes AIDS. Since then, more than 60 million people have been infected with HIV and last year, 2.1 million people died of AIDS. Although progress has been made in delivering lifesaving treatments and identifying effective prevention strategies, fin
U.S. Department of Health and Human Services; National Institutes Of Health; NIH News; National Institute of Allergy and Infectious Diseases (NIAID)
CONTACT: NIAID News Office, 301-402-1663,
Twenty-five years ago this month, researchers reported the isolation of the virus that causes AIDS. Since then, over 60 million people have been infected with HIV -- an estimated 2.5 million in 2007 alone -- numbers that remind us that the development of an HIV vaccine is an urgent humanitarian imperative. This year s
National Institute of Allergy and Infectious Diseases; National Institutes of Health
NIAID Online Update - May 12, 2008
The incidence of AIDS is on the rise among Asians and Pacific Islanders. Unfortunately, evidence suggests that they get tested for HIV at lower rates than other U.S. populations despite a comparable risk of HIV infection. To commemorate National Asian and Pacific Islander HIV/AIDS Awareness Day on May 19, Anthony S. Fa
U.S. Department of Health and Human Services; National Institutes Of Health; National Institute of Allergy and Infectious Diseases (NIAID); NIAID Online Update - April 25, 2008
WHAT: The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), is seeking broad input to spur new ideas and approaches in the areas of vaccine discovery research and HIV prevention research through two new Requests for Information a comment-gathering tool use
U.S. Department of Health and Human Services; National Institutes Of Health; National Institute of Allergy and Infectious Diseases (NIAID) - For Immediate Release: Tuesday, April 22, 2008
Contact: NIAID News Office, 301-402-1663,
Tuberculosis (TB) has long been one of the world s great killers. Now, forms of drug-resistant TB-multidrug (MDR) and extensively drug-resistant (XDR)-are occurring at an ominous and accelerating rate. To help in the fight against drug-resistant TB, the National Institute of Allergy and Infectious Diseases (NIAID), par
National Institute of Allergy and Infectious Diseases (NIAID), National Institutes Of Health (NIH)
NIAID Online Update - March 24, 2008
As we commemorate World TB Day, we recognize the important strides made in combating tuberculosis (TB) over the past several years, and, simultaneously, are reminded of the substantial challenges that lie ahead. Nearly one-third of the world’s population is infected with Mycobacterium tuberculosis (Mtb), the bacterium
U.S. Department of Health and Human Services; National Institutes Of Health; National Institute of Allergy and Infectious Diseases (NIAID) - NIAID Online Update - March 20, 2008
On Tuesday, March 25, 2008, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, will host an HIV Vaccine Summit in Bethesda, Md. as an important step in the ongoing process to examine the current direction of HIV vaccine research. WHAT: On Tuesday, March 25, 200
U.S. Department of Health and Human Services; National Institutes Of Health; NIH News; National Institute of Allergy and Infectious Diseases (NIAID): Monday, March 20, 2008
Contact: NIAID Office of Communications, 301-402-1663,
Today, on the second annual National Native HIV/AIDS Awareness Day, we reflect on the significant toll of HIV/AIDS on native people, including American Indians, Alaska Natives and Native Hawaiians. The estimated rate of HIV/AIDS diagnoses for American Indians and Alaska Natives in 2005 was 18 percent higher than the ra
U.S. Department of Health and Human Services; National Institutes Of Health; NIH News; National Institute of Allergy and Infectious Diseases (NIAID): Monday, March 10, 2008
Contact: NIAID Office of Communications, 301-402-1663, e-mail: niaidnews@niaid.nih.gov
Today, we pause to commemorate the third annual National Women and Girls HIV/AIDS Awareness Day and to recognize the female face of HIV/AIDS in America. Since the epidemic began in the early 1980s, more than 181,000 women and girls in the United States have been diagnosed with AIDS, and an estimated 86,000 have died wi
National Institute of Allergy and Infectious Diseases (NIAID), National Institutes Of Health (NIH) - March 6, 2008
On February 28, NIAID announced that it modified an HIV antiretroviral treatment study in HIV-infected participants who had never taken anti-HIV drugs. The study, known as ACTG 5202, was modified because one of the four drug regimens ( abacavir /lamivudine) under investigation was not as effective at controlling the vi
U.S. Department of Health and Human Services; National Institutes Of Health; NIH News; National Institute of Allergy and Infectious Diseases (NIAID) - Sunday, February 10, 2008
CONTACT: NIAID Office of Communications, 301-402-1663, e-mail: niaidnews@niaid.nih.gov
A cellular protein that helps guide immune cells to the gut has been newly identified as a target of HIV when the virus begins its assault on the body s immune system, according to researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The id
U.S. Department of Health and Human Services; National Institutes Of Health; NIH News; National Institute of Allergy and Infectious Diseases (NIAID) - Tuesday, February 5, 2008
CONTACT: NIAID Office of Communications, 301-402-1663, e-mail: niaidnews@niaid.nih.gov
The grossly disproportionate impact of HIV/AIDS on African Americans is a public health crisis that we at the National Institutes of Health (NIH) and as a nation must address boldly. Nearly 27 years into the AIDS epidemic, approximately half of the new HIV infections that occur each year in the United States a
U.S. Department of Health and Human Services; National Institutes Of Health; NIH News; National Institute of Allergy and Infectious Diseases (NIAID) - Monday, February 4, 2008
Vaccines have led to many of the world s greatest public health triumphs, but many deadly viruses, such as HIV, still elude the best efforts of scientists to develop effective vaccines against them. An improved understanding of how the immune system operates during a viral infection is critical to designing successful
U.S. Department of Health and Human Services; National Institutes Of Health; NIH News; National Institute of Allergy and Infectious Diseases (NIAID) - Monday, January 21, 2008
Contact: Ken Pekoc, 406-375-9690, e-mail: pekoc@niaid.nih.gov
Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infections are caused primarily by a single strain -- USA300 -- of an evolving bacterium that has spread with extraordinary transmissibility throughout the United States during the past five years, according to a new study led by National Instit
This information is designed to support, not replace, the relationship that exists between you and your doctor.